CoChat

Combination phentermine and topiramate extended release in the management of obesity.

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Losing ≥ 5% of initial weight improves quality of life and risk factors for cardiovascular disease (CVD) in obese individuals. Lifestyle modification, the cornerstone of weight reduction, may be complemented by pharmacotherapy. In 2012, the FDA approved the combination of phentermine and topiramate extended release (ER) for chronic weight management, as an adjunct to lifestyle modification. AREAS COVERED: This review examines the safety and efficacy of phentermine-topiramate ER, as determined by randomized controlled trials (RCTs). A preliminary study confirmed the benefit of combining the two medications for improving weight loss and reducing adverse effects, as compared to using equivalent-dose monotherapy alone. EXPERT OPINION: Across RCTs, groups prescribed phentermine 15 mg/topiramate ER 92 mg lost an average of 10% of initial weight, ∼ 8% more than placebo and 2% more than phentermine 7.5 mg/topiramate 46 mg. Weight loss reduced the risk of developing type 2 diabetes and improved CVD risk factors. Phentermine-topiramate ER, however, was associated with increased heart rate, the clinical significance of which is being investigated in an FDA-required CVD outcomes study. The medication also must be used with caution in women of child-bearing age because of an increased risk to infants of oral cleft.

Overview

Integrity signals

Registry

Crossref · 10.1517/14656566.2015.1041505

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 4

  1. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 2014;22(Suppl 2):S5-39
  2. National Center for Biotechnology Information. PubChem Compound Database CID=4771 Available from: http://pubchem.ncbi.nlm.nih.gov/compound/phentermine [Accessed on 16 December 2014]
  3. Qsymia [package insert]. VIVUS, Inc; Mountain View, CA 2014
  4. Brownell KD. The LEARN program for weight management. The Life Style Co; Dallas: 2000

Cited by

See all 41

Metadata

Authors
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A.
Affiliations
University of Pennsylvania (US)
Venue
Expert Opinion on Pharmacotherapy
Published
2015-05-09
Volume
16
Issue
8
Pages
1263-1274
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W1958745756
Cited by
38
References
54
Citations by year
2026: 3 · 2025: 5 · 2024: 3 · 2023: 7 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 2
FWCI
0.54
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, weight loss, obesity pharmacotherapy, lifestyle modification, type 2 diabetes prevention, cardiovascular risk factors, heart rate, pregnancy, drug safety and efficacy
MeSH terms
Topiramate, Cardiovascular Diseases, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Combinations, Fructose, Humans, Life Style, Obesity, Phentermine, Risk Factors, Weight Loss, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Anti-Obesity Agents, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination phentermine and topiramate extended release in the management of obesity. https://app.cochat.ai/papers/10.1517/14656566.2015.1041505
The paper
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015). Combination phentermine and topiramate extended release in the management of obesity. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1041505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.